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Abstract. Intraoperative margin assessment is imperative to cancer cure but is a continued challenge to
successful surgery. Breast conserving surgery is a relevant example, where a cosmetically improved outcome
is gained over mastectomy, but re-excision is required in >25% of cases due to positive or closely involved
margins. Clinical translation of margin assessment modalities that must directly contact the patient or required
administered contrast agents are time consuming and costly to move from bench to bedside. Tumor resections
provide a unique surgical opportunity to deploy margin assessment technologies including contrast agents on
the resected tissues, substantially shortening the path to the clinic. However, staining of resected tissues is
plagued by nonspecific uptake. A ratiometric imaging approach where matched targeted and untargeted probes
are used for staining has demonstrated substantially improved biomarker quantification over staining with con-
ventional targeted contrast agents alone. Our group has developed an antibody-based ratiometric imaging tech-
nology using fluorescently labeled, spectrally distinct targeted and untargeted antibody probes termed dual-stain
difference specimen imaging (DDSI). Herein, the targeted biomarker expression level and pattern are evaluated
for their effects on DDSI diagnostic potential. Epidermal growth factor receptor expression level was correlated to
DDSI diagnostic potential, which was found to be robust to spatial pattern expression variation. These results
highlight the utility of DDSI for accurate margin assessment of freshly resected tumor specimens. © The Authors.
Published by SPIE under a Creative Commons Attribution 4.0 Unported License. Distribution or reproduction of this work in whole or in part requires full
attribution of the original publication, including its DOI. [DOI: 10.1117/1.JBO.24.2.026002]
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1 Introduction
Through implementation of widespread mammography screen-
ing programs in the United States, a substantial number of early
stage breast cancers are now detected.1,2 One of the most
common treatments for early stage breast cancer is breast con-
serving surgery (BCS) or lumpectomy.3 While cosmetically
improved over mastectomy, BCS can have re-excision rates
ranging from 23% to 38% due to close or involved tumor mar-
gins as determined through comprehensive histopathological
analysis following surgery.4,5 Any findings of close or involved
margins require immediate follow-up surgery, which increases
patient stress and risk of morbidity, reducing the likelihood of a
positive outcome.6–9 Thus, it is important that the entire tumor is
removed during the primary surgery to minimize re-excision
rates as well as risk for local recurrence.10 A number of intra-
operative margin analysis technologies have been developed to
reduce re-excision rates, including frozen section analysis and
touch prep cytology, which have been deployed clinically.11,12
However, none of the current intraoperative margin assessment
techniques have been able to counter the current re-excision
rate due to lack of sensitivity and specificity and/or challenges
in adopting these procedures into the standard surgical
workflow.13–18 Therefore, the need for a robust, accurate intra-
operative margin assessment technology to guide BCS remains.
To address this challenge, several groups have examined the
utility of tissue staining techniques on resected specimens to
help identify positive margins during surgery. One such tech-
nique, which we termed dual-stain difference specimen imaging
(DDSI), involves the use of a biomarker-targeted fluorescent
probe and a spectrally distinct untargeted isotype control
probe to normalize the images and emphasize targeted-probe
binding.19–26 A variety of probes have been examined for this
application by our group and others, including epidermal growth
factor receptor (EGFR), human epidermal growth factor recep-
tor 2 (HER2), estrogen receptor (ER), and CD44, where target-
ing the extracellular domain of receptors has shown the best
performance.19,20,25 Previously, we reported on an extensive
staining optimization study for HER2-targeted DDSI. This
study resulted in a DDSI staining methodology that accurately
reported HER2-specific expression, predicting tumor tissue from
normal adipose tissue with 91% sensitivity and 84% specificity
on a testing data set of both high and low HER2-expressing
tumors.19 However, the relationship between DDSI performance
and the expression level of the targeted biomarker has yet to be
examined and quantified.
In this work, we used receiver operator characteristic (ROC)
curve analysis to examine the relationship between receptor
expression level and diagnostic performance of DDSI in tumors
with varying levels of EGFR expression, a receptor overexpressed
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in some triple negative breast cancers.27 Three cell lines with
varied EGFR expression were grown as xenografts in the murine
mammary adipose pads as a model system to evaluate DDSI
contrast following resection of tumors with varied biomarker
expression levels. In addition, we examined the effect of tumor
biomarker spatial heterogeneity on the diagnostic performance
of DDSI in these model systems using ROC curve analysis.
2 Materials and Methods
2.1 General Study Design
1. The previously optimized DDSI protocol19 was applied
to xenografts derived from cell lines with varied levels
of EGFR expression, and the diagnostic performance
was quantified using ROC curve analysis.
2. The optimal DDSI analysis method for biomarker
heterogeneity was assessed, where standard cumula-
tive tissue analysis was compared to cumulative and
concentric ring analyses. ROC curve analysis was used
to determine diagnostic performance of each method
for optimal use in future studies.
Each tumor xenograft replicate was compared to surrounding
mammary adipose and muscle tissues for diagnostic potential
(n ¼ 20 tumor–normal tissue pairs per cell line), resulting in
a total of 60 tumor–normal tissue pairs that were stained with
the previously optimized DDSI protocol. Coregistered color,
targeted, and untargeted probe images were captured using a
custom-build, wide-field imaging system. DDSI image process-
ing was completed using custom written MatLab code and
DDSI diagnostic performance was evaluated using ROC curve
analysis. Tissue type and EGFR expression levels were con-
firmed using gold standard hematoxylin and eosin (H&E) and
immunohistochemistry (IHC) staining, respectively.
2.2 Fluorophores and Antibodies
Alexa Fluor 647 (AF647, Thermo Fisher Scientific, Waltham,
Massachusetts) and Cy3B (GE Healthcare Life Sciences,
Little Chalfont, United Kingdom) were purchased in their N-
hydroxysuccinimidyl ester form and solubilized in anhydrous
dimethyl sulfoxide (DMSO) at 10 mM for antibody conjugation.
Cetuximab [Erbitux, Eli Lilly and Company, Branchburg,
New Jersey, molecular weight (MW) = 152 kDa] was used
as the targeted probe. Donkey anti-Rabbit IgG (DkRb,
Jackson ImmunoResearch, West Grove, Pennsylvania, MW =
150 kDa) was used as the untargeted probe.
2.3 Cell Lines and Flow Cytometry
The human epidermoid carcinoma cell line A431, human pan-
creatic adenocarcinoma cell line AsPC-1, and human breast
adenocarcinoma cell line MDA-MB-231 were cultured in
DMEM 1× (Thermo Fisher Scientific) supplemented with
10% fetal bovine serum (FBS, Seradigm, Sanborn, New York)
and 1% penicillin–streptomycin–glutamine (Thermo Fisher
Scientific). All cell lines were grown to ∼90% confluence
prior to trypsinization and subsequent preparation for EGFR
quantification by flow cytometry. The suspended cells were
pelleted at 1000 rpm for 5 min prior to resuspension in 4%
paraformaldehyde (PFA, Sigma-Aldrich, St. Louis, Missouri)
for 15 min. The fixed cells were pelleted again to remove PFA,
after which they were blocked in 5% FBS for 15 min. The cells
were then stained with cetuximab conjugated to AF647 (fluo-
rophore-to-protein conjugation ratio of 2 to 3 for flow cytometry
studies) at 250-nM protein concentration for 2 h at room temper-
ature. The stained cells were pelleted, washed three times with
phosphate buffered saline (PBS), fixed in 4% PFA for 15 min,
and washed three additional times with PBS. The stained cell
pellets were resuspended in PBS to a final concentration of
1 × 106 cells∕mL, where triplicate samples per cell line were
quantified using flow cytometry. Additional unstained cells
were prepared for each cell line as a negative control in triplicate
per cell line.
All flow cytometry experiments were conducted on a Becton
Dickinson LSRII (Becton Dickinson Company, Franklin Lakes,
New Jersey) flow cytometer. The flow cytometer was configured
with a 633 (660/20) Cy5 channel, which was used to detect
AF647 (excitation maximum: 650 nm, emission maximum:
665 nm). Prior to analyzing cells, Quantum™ AF647 molecular
equivalents of soluble fluorophore beads (Bangs Laboratories,
Inc., Fishers, Indiana) were analyzed to enable receptor-based
quantification of EGFR per cell. 10,000 cells per samples
were counted and the data were analyzed using FlowJo software
(FlowJo, LLC, Ashland, Oregon).
2.4 Mice, Tumor Implantation, and Growth
All animal studies were approved by the Institutional Animal
Care and Use Committee at Oregon Health and Science
University (OHSU). Female athymic nude mice (32 to 38
days old, homozygous 490, Charles River Laboratories,
Wilmington, Massachusetts) weighing 19 to 21 g were used
to grow xenografts of each of the three selected cell lines.
Mice were anesthetized using 100 mg∕kg ketamine (Hospira
Inc., Lake Forest, Illiois) and 10 mg∕kg xylazine (AnaSed,
Shenandoah, Iowa) administered by intraperitoneal injection.
Depth of anesthesia was accessed using the toe pinch method
prior to tumor implantation.
In a sterile field, the peritoneal area was sterilized using povi-
done-iodine (Purdue Products, Stamford, Connecticut). A small
incision (3 to 5 mm) was made along the lateral side of each
inferior nipple. Using forceps, mammary adipose was extracted
though the incision and 200 μL of cell suspension (1 × 106
cells) were injected. The mammary adipose was inserted back
through the incision, and it was sealed with Vetbond™ (3M,
St. Paul, Minnesota). Mice were monitored daily following
the procedure to ensure healing for 5 to 7 days and then weekly
for tumor growth and overall health.
Tumors were allowed to grow to a maximum size of 1.5 cm3
which was reached in 10 to 14 days for A431, 4 to 5 weeks for
AsPC-1, and 3 to 4 weeks for MDA-MB-231 xenografts. Each
cell line was implanted into a cohort of five mice, where two
tumors per mouse were implanted. This resulted in n ¼ 20
tumor samples per cell line following bisection of the resected
tumor prior to DDSI staining.
2.5 Antibody–Fluorophore Conjugations
Cetuximab was conjugated to AF647, and DkRb was conju-
gated to Cy3B. Antibody conjugations to their respective
fluorophore were completed as previously described.19 The
fluorophore-to-protein ratio of each conjugate was quantified
using absorbance spectroscopy (SpectraMax M5, Molecular
Devices, San Jose, California) with the antibody absorbance
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measured at 280 nm [cetuximab and DkRb extinction coefficient
ðεÞ ¼ 210;000 M−1 cm−1], Cy3B absorbance measured at
560 nm (Cy3B ε ¼ 130;000 M−1 cm−1), and AF647 absorbance
measured at 650 nm (AF647 ε ¼ 270;000 M−1 cm−1). All flu-
orophore-to-antibody ratios were between 3:1 and 4:1 for DDSI
staining studies. The DDSI staining solution was made from a
mixture of the cetuximab-AF647 and DkRb-Cy3B conjugates in
1× PBS, pH 7.4, 0.1% Tween 20, and 1% bovine serum albumin
(BSA) at a final concentration 200 nM of each antibody as
measured by protein concentration.
2.6 Tumor Resection and DDSI Staining
All mice were euthanized using carbon dioxide asphyxiation
followed by cervical dislocation. Tumors were excised and
bisected resulting in two samples from each tumor. For each
tumor sample, a corresponding mammary adipose sample
was harvested from the chest, and a muscle sample was
harvested from the posterior thigh of each mouse. Each tumor,
adipose, and muscle group was stained and washed together
following the previously published DDSI staining procedure,19
described in brief as follows. Tumor and normal tissues were
blocked by incubating in 1 mL of 2% BSA in 1× PBS for
10 min, followed by a 1-min incubation in 1 mL of 200 nM
cetuximab-AF647 and DkRb-Cy3B. The stained tissue samples
were then washed in 50 mL of 0.1% Tween-20 in 1× PBS under
gentle agitation for 5 min. The stained tumor and normal tissues
were imaged on glass slides with the bisected side facing the
light source and camera.
2.7 DDSI Macroscopic Imaging
Color and fluorescence images of tumor and normal tissue pairs
were collected using a previously described custom-built wide
field imaging system,28 detailed briefly as follows. The macro-
scopic fluorescence imaging system consisted of a QImaging
EXi Blue monochrome camera (Surrey, British Columbia,
California) with a removable Bayer filter and a PhotoFluor II
light source (89 North, Burlington, Vermont). The light source
was outfitted with 545 12.5 nm or 620 30 nm bandpass
excitation filter for Cy3B or AF647, respectively. A 605
35 nm or a 700 37.5 nm bandpass emission filter was placed
in front of the camera for detection of Cy3B or AF647 fluores-
cence emission, respectively. All filters were obtained from
Chroma Technology (Bellows Falls, Vermont). An aliquot of
the staining solution was placed in a covered optical well
plate (Greiner Bio-One, Monroe, North Carolina) and imaged
with each tumor and normal tissue pair for image calibration.
2.8 DDSI Processing
The targeted and untargeted fluorescence images were used to
calculate DDSI using custom written MatLab code (MathWorks,
Natick, Massachusetts) described briefly as follows. Regions of
interest (ROIs) were selected for background signal in which
median signal was subtracted from the entire image. An ROI
was also selected from the DDSI staining solution for intensity
normalization between fluorescence channels, where each pixel
value in each fluorescence image was divided by the average
intensity value of the ROI selected within the DDSI staining sol-
ution. Tumor or normal tissue ROIs were selected using white
light images and used to mask each fluorescence image. DDSI
was calculated as IDDSI ¼ ðITargeted − IUntargetedÞ∕IUntargeted,
where I is the fluorescence signal intensity.
2.9 IHC Staining and Microscopy
Immediately after completion of the DDSI stain protocol, each
tumor and normal tissue pair was flash frozen in optimal cutting
temperature (Fisher HealthCare, Houston, Texas) compound for
tissue preservation and to maintain tumor orientation. All tissue
blocks were sent to the OHSU Histology Shared Resource Core
where they were thawed and re-embedded in paraffin, maintain-
ing tissue orientation. The formalin-fixed paraffin embedded
tissue blocks were faced prior to collection of a representative
section of the tumor, adipose, and muscle pieces. IHC staining
was performed on 4-μm sections using an EGFR antibody
(1:300, clone EP38Y, AbCam, Cambridge, Massachusetts) tar-
geted to a different epitope to prevent steric hindrance with pre-
existing labeling from cetuximab. Serial sections were used for
gold standard H&E staining. Due to the tissue processing and
sectioning necessary to generate sections of the tumor, muscle,
and adipose pieces, the same tissue face that was imaged
macroscopically using DDSI was not able to be sampled micro-
scopically. However, the IHC- and H&E-stained sections pro-
vide representative EGFR expression and necrotic region tissue
maps, respectively, for each tumor. Bright field images of all
IHC- and H&E-stained slides were collected at 10× magnifica-
tion using the Zeiss AxioScan.Z1 (Carl Zeiss Microscopy
GmbH, Jena, Germany). ROIs of the IHC and H&E slides
were detected using the Automatic Tissue Recognition feature
in the ZEN software (Zeiss). Six fields of view were used to
set the focus map prior to image scanning and tiling of each
H&E- and IHC-stained sections.
2.10 Statistical Analysis
As previously described, statistical analysis was performed
using MatLab.19 In brief, tumor-to-normal tissue diagnostic
detection was assessed through the calculation of ROC curves
from DDSI. ROC curves and corresponding area under the
curve (AUC) measurement were calculated using MatLab on
a pixel-by-pixel basis. Briefly, a threshold variable was gener-
ated with a linearly increasing value from the minimum to maxi-
mum pixel intensity value. The threshold variable was then used
to generate the true-positive rate (% of tumor pixels greater than
the threshold, TPR), false-positive rate (% of normal pixels less
than the threshold, FPR), ROC curves, and the corresponding
AUC values by plotting these values at each threshold value.
Three methods were employed to select the tumor pixels
used to quantify the DDSI ROC curves including (1) standard
cumulative tissue analysis as previously described,19 (2) cumu-
lative ring analysis, and (3) concentric ring analysis. For the
(1) standard cumulative tissue analysis, tumor pixel values
were taken from the entire tumor tissue area and used for
ROC analysis of tumor versus normal tissue diagnostic poten-
tial. For the (2) cumulative ring analysis, an iterative analysis
was completed, where tumor pixel values were taken from
rings starting at the edge of the tumor (0.1 mm in depth),
where the ring depth was increased by 0.1 mm for each iteration.
The cumulative rings were moved into the tumor up to 3 mm
from the edge and progressively more tumor pixels from the
edge were included in the ROC curve analysis to differentiate
tumor versus normal tissue. For the (3) concentric ring analysis,
an iterative analysis was completed where tumor pixel values
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were taken from rings starting at the edge of the tumor at a set
width of 0.1 mm. The ring location was moved concentrically
inward up to 3 mm from the tumor edge, where only the tumor
pixels contained within the 0.1-mm wide ring at the specific
depth from the tumor edge were used in the tumor versus normal
tissue ROC curve analysis. Both the cumulative and concentric
ring analysis methods utilized the MatLab imerode function
to obtain regular rings with minimal variation upon further
inclusion. Normal tissue pixel values were taken from the entire
normal tissue area in all analysis methods.
3 Results
3.1 Diagnostic Performance of DDSI Correlates
with EGFR Expression Level
Three cell lines with varied EGFR expression (A431, AsPC-1,
and MDA-MB-231) were used to characterize the relationship
between diagnostic performance of DDSI staining and bio-
marker overexpression level. A431 cells had the highest
EGFR expression (2.5 × 106 receptors∕cell), AsPC-1 cells
had mid-level EGFR expression (2.9 × 105 receptors∕cell),
and MDA-MB-231 cells had the lowest EGFR expression
(1.3 × 105 receptors∕cell, Fig. 1). Qualitative assessment of cal-
culated DDSI as compared to the targeted and untargeted fluo-
rescence images showed an improved match between signal
intensity and biomarker expression as determined by gold stan-
dard H&E and IHC. Comparison of the targeted and untargeted
fluorescence images with the corresponding IHC and H&E
demonstrated that the targeted and untargeted probes uptake
was highest in the necrotic regions, which was corrected
using DDSI calculations (Fig. 2). DDSI for the lower EGFR-
expressing AsPC-1 and MDA-MB-231 xenografts were plotted
on the same scale as the highly EGFR-expressing A431 tumors,
where DDSI intensity was not as obvious for the lower EGFR-
expressing tumors (Fig. 2). However, examination of a cohort of
representative DDSI, H&E, and IHC images from each tumor
Fig. 1 Quantified EGFR expression Levels. EGFR expression was
quantified in vitro via flow cytometry using cetuximab directly labeled
with AF647. The autofluorescence level of each cell line was quanti-
fied as a negative control on unstained cells.
Fig. 2 Representative staining patterns from varied EGFR-expressing xenografts. A representative
(a) A431, (b) AsPC-1, and (c) MDA-MB-231 tumor and corresponding mammary adipose and muscle
tissue are shown as color, untargeted fluorescence, targeted fluorescence, DDSI, H&E-, and EGFR-
stained IHC. All images are representative of n ¼ 20 tumor, mammary adipose, and muscle tissue
sets per tumor type. The untargeted and targeted fluorescence images were background corrected
using their exposure time(s) and calibration drop intensities. An equivalent color scale, optimal for
A431 xenografts, was used to display untargeted, targeted, and DDSI calculated images. IHC and
H&E images were collected via serial sections from formalin-fixed paraffin embedded tissue blocks.
IHC, immunohistochemistry; H&E, hematoxylin and eosin; T, tumor; A, mammary adipose; M, muscle.
Scale bar = 5 mm.
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type showed that DDSI intensity was representative of bio-
marker expression, when each tumor type was plotted on its
optimal intensity scale (Fig. 3). Additionally, EGFR expression
patterns were found to differ across xenograft types. The A431
tumors showed relatively homogeneous EGFR expression
[Figs. 2(a) and 3(a)]. By comparison, the AsPC-1 and MDA-
MB-231 tumors both showed heterogeneous EGFR expression
with notable necrotic regions, where there were either minimal
cells or minimal EGFR expression [Figs. 2(b) and 2(c)], which
was true throughout the sample population [Figs. 3(b) and 3(c)].
Tumor-to-adipose and tumor-to-muscle DDSI diagnostic
potential was quantitatively evaluated using ROC curve analysis
for all A431, AsPC-1, and MDA-MB-231 replicates, where the
AUCwas used as the metric for comparison between xenografts.
ROC curves for the tumor-to-adipose DDSI showed high diag-
nostic potential for the A431 tumors [AUC ¼ 0.95, Fig. 4(a)],
which had both relatively homogeneous EGFR expression as
well as the highest EGFR expression level compared to the
AsPC-1 or MDA-MB-231 tumors (Figs. 2 and 3). The EGFR
expression level was well correlated with tumor-to-adipose
DDSI diagnostic potential as demonstrated by the AUC for
the three cells lines (AUC: A431 = 0.95, AsPC-1 = 0.91, and
MDA-MB-231 = 0.67). However, this correlation was not linear
as the EGFR expression level of the A431 cells was an order of
magnitude higher than AsPC-1 cells (Fig. 1), and the DDSI
AUCs were relatively similar between these two tumor types.
Notably, the MDA-MB-231 xenografts, which had roughly
half the EGFR expression of the AsPC-1 tumors, showed con-
siderably lower tumor-to-adipose DDSI diagnostic potential
based on the AUC [Fig. 4(a)]. ROC curves for the tumor-to-
muscle DDSI ratios were substantially improved over the
tumor-to-adipose DDSI ratios, where AUCs for all tumor xen-
ografts were ≥0.95 [Fig. 4(b)]. When the ROC curve calculated
AUC values for each replicate were evaluated, the standard
deviation for the tumor-to-adipose DDSI was substantially
larger than the tumor-to-muscle DDSI. In addition, the standard
deviation increased with decreasing EGFR expression [Fig. 4(c)].
The ROC curve calculated AUC for tumor-to-adipose and
tumor-to-muscle contrast for the targeted and untargeted chan-
nels alone were not well correlated with EGFR expression
levels [Figs. 4(d)–4(h)]. Tumor-to-adipose ROC curve calcu-
lated AUC was higher for the targeted channel than for DDSI
for the lower EGFR-expressing AsPC-1 and MDA-MB-231
tumor lines, demonstrating the incongruent quantification by
comparison to the EGFR expression level (Figs. 1 and 4).
In addition, when ROC curve calculated AUC values for each
replicate were considered for the targeted [Fig. 4(f)] and untar-
geted [Fig. 4(I)] probes alone, much larger standard deviation
was seen than for the ROC curve calculated AUC for the DDSI
[Fig. 4(c)], showing the enhanced consistency in tumor-to-
normal tissue contrast using DDSI instead of targeted probe
staining alone.
3.2 Necrotic Tissue Does Not Substantially Alter
DDSI Diagnostic Potential
The effect of the calculated ROC curve AUC DDSI variability
[Fig. 4(c)] and observed necrotic regions in the AsPC-1 and
MDA-MB-231 tumors (Figs. 2 and 3) was further investigated.
The influence of these necrotic regions and thus heterogeneous
EGFR expression on DDSI was assessed by comparing three
DDSI analysis techniques including (1) standard cumulative
tissue analysis (Fig. 4), (2) cumulative ring analysis (Fig. 5),
and (3) concentric ring analysis (Fig. 6). The cumulative ring
analysis was performed by drawing concentric circles at inter-
vals of 0.1 mm from the edge of each tumor for up to a total
depth of 3 mm into the tumor, where each subsequent DDSI
analysis included the previous 0.1 mm (Fig. 5). This analysis
method served to omit much of the necrotic regions of the
AsPC-1 and MDA-MB-231 tumors from the DDSI analysis.
DDSI ROC curve calculated AUC at 2 mm showed no increase
in AUC for the A431 tumors compared to the cumulative tissue
Fig. 3 DDSI staining validation and IHC analysis. A cohort of representative images from (a) A431,
(b) AsPC-1, and (c) MDA-MB-231 tumors, mammary adipose, and muscle tissues are shown in
color, DDSI, and EGFR-stained IHC. All images are representative of n ¼ 20 tumor, mammary adipose,
and muscle tissue sets per tumor type. DDSI calculated images are displayed on their respective optimal
scale for each tumor type (see color bars on the right). IHC, immunohistochemistry.
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analysis, whereas only a slight increase was seen for the AsPC-1
and MDA-MB-231 tumors [Figs. 5(a)–5(c)]. Notably, at the
2-mm depth of edge, the standard deviation between the ROC
curve calculated AUCs of the tumor-to-adipose and tumor-to-
muscle for each tumor line were substantially decreased com-
pared to the cumulative tissue analysis [Figs. 4(c) and 5(d)].
Marginal change was seen in ROC curve calculated AUC
using the cumulative tissue analysis method at up to 3 mm
depth of edge (0.1 to 3 mm ROC calculated AUC range for
tumor-to-adipose contrast: A431 = 0.88 to 0.95, AsPC-1 =
0.92 to 0.93, and MDA-MB-231 = 0.67 to 0.71) and thus,
the 2-mm depth was selected as a representative example.
Fig. 4 Cumulative tissue analysis ROC curves and calculated AUC of varied EGFR-expressing xeno-
grafts. The lumped DDSI (a) tumor to adipose and (b) tumor to muscle cumulative tissue ROC curves for
A431 (blue), AsPC-1 (green), and MDA-MB-231 (red) xenografts are shown for n ¼ 20 tumor-to-adipose
or tumor-to-muscle tissue pairs per cell line, respectively. (c) The DDSI ROC curve calculated AUC
values for each of the 20 tumor-to-adipose and tumor-to-muscle pairs per cell line are plotted where
the median, interquartile range, and standard deviation are shown. The lumped targeted (d) tumor-
to-adipose and (e) tumor-to-muscle cumulative tissue ROC curves for A431 (blue), AsPC-1 (green),
and MDA-MB-231 (red) xenografts are shown for n ¼ 20 tumor-to-adipose or tumor-to-muscle tissue
pairs per cell line, respectively. (f) The targeted ROC curve calculated AUC values for each of the
20 tumor-to-adipose and tumor-to-muscle pairs per cell line are plotted where the median, interquartile
range, and standard deviation are shown. The lumped untargeted (g) tumor-to-adipose and (h) tumor-to-
muscle cumulative tissue ROC curves for A431 (blue), AsPC-1 (green), and MDA-MB-231 (red) xeno-
grafts are shown for n ¼ 20 tumor-to-adipose or tumor-to-muscle tissue pairs per cell line, respectively.
(i) The untargeted ROC curve calculated AUC values for each of the 20 tumor-to-adipose and tumor-to-
muscle pairs per cell line are plotted where the median, interquartile range, and standard deviation are
shown. ROC, receiver operator characteristic; AUC, area under the curve.
Journal of Biomedical Optics 026002-6 February 2019 • Vol. 24(2)
Schaefer et al.: Diagnostic performance of receptor-specific surgical specimen staining correlates. . .
Downloaded From: https://www.spiedigitallibrary.org/journals/Journal-of-Biomedical-Optics on 26 Jul 2019
Terms of Use: https://www.spiedigitallibrary.org/terms-of-use
The concentric ring analysis was performed by assessing
DDSI in concentric 0.1 mm rings drawn from the edge of
the tumor and analyzed individually [Fig. 6(a)]. DDSI ROC
curve calculated AUCs for the A431 tumors were slightly
increased using this analysis method compared with analyzing
DDSI for the cumulative tissue [Fig. 6(b)]. In contrast, the DDSI
tumor-to-adipose ROC curve calculated AUCs were sharply
decreased for the AsPC-1 and MDA-MB-231 tumors when
the concentric rings were moved closer to the center of the
tumor, where the bulk of the low EGFR expression was located
[Figs. 3(b), 3(c), and 6(b)]. This DDSI trend was even apparent
in the tumor-to-muscle ROC curve calculated AUC values for
AsPC-1 tumors, which had been stable for the other analyses,
although the difference between the AUC values was much
smaller [Fig. 6(c)].
4 Discussion
The primary goal of this study was to understand how the targeted
cancer biomarker expression level correlated to DDSI staining
diagnostic accuracy for intraoperative margin assessment, with
a focus on BCS. BCS is the preferred treatment method for early
stage breast cancer due to its improved cosmetic results and
equivalence in patient survival to mastectomy.3 However, the
prevalence of incomplete tumor removal and positive margin
status remains problematic, where positive margin status is
correlated with local recurrence.2,6–9 While a variety of targeted
contrast agents have been developed for intraoperative cancer
delineation,29–32 translation to the clinic is expensive and time
consuming and to date few cancer-specific probes have been
moved from bench to bedside.33–35 To facilitate the use of fluo-
rescence-guided surgery for intraoperative margin assessment,
we have developed DDSI to stain resected tissues so the contrast
agents never touch the patient, significantly shortening the path
to the clinic. DDSI utilizes ratiometric imaging of matched
biomarker targeted and untargeted probes, which enables
quantitative correction for nonspecific probe uptake, a prevalent
problem when staining resected tissue specimens.19,20,22,25
Using our previously optimized DDSI methodology,19
we evaluated the accuracy of DDSI to differentiate between
tumor and normal tissues (adipose or muscle) where model
Fig. 5 Cumulative ring analysis ROC curves and calculated AUC of varied EGFR-expressing xenografts.
Cumulative ring ROC curve analysis was employed at iterations of 0.1 mm intervals from the tumor edge
with 2 mm cumulative analysis shown as a representative example. (a) Representative color and DDSI
calculated images from each tumor type with DDSI shown on the optimal scale for A431 tumors. The
lumped (b) tumor-to-adipose and (c) tumor-to-muscle ROC curve cumulative ring analysis at 2 mm is
shown for n ¼ 20 A431 (blue), AsPC-1 (green), and MDA-MB-231 (red) tumors. (d) The ROC curve
calculated AUC values for each of the 20 tumor-to-adipose and tumor-to-muscle pairs per cell line
are plotted where the median, interquartile range, and standard deviation are shown. ROC, receiver
operator characteristic; AUC, area under the curve; scale bar = 5 mm.
Fig. 6 Concentric ring analysis ROC curves calculated AUCs of varied EGFR-expressing xenografts.
(a) Concentric ring ROC curve analysis was employed at iterations of 0.1 mm from the tumor edge up to
3 mm into each tumor sample, where DDSI of each ring was quantified individually. A representative
example DDSI ring is shown. The lumped (b) tumor-to-adipose and (c) tumor-to-muscle ROC curve cal-
culated AUC values at varied depth from the edge of the tumor for A431 (blue), AsPC-1 (green), and
MDA-MB-231 (red) were calculated and are displayed over the total depth of edge calculated. For refer-
ence, the standard cumulative tissue analysis ROC curve calculated AUC are shown as solid dots on
the right-hand side of each plot. ROC, receiver operator characteristic; AUC, area under the curve;
scale bar = 5 mm.
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tumors with varied biomarker expression were assessed (Fig. 1).
In addition to varied EGFR expression levels, these tumor mod-
els also presented heterogeneous spatial patterns of biomarker
expression (Figs. 2 and 3), facilitating quantification of the
effect of biomarker expression on DDSI diagnostic potential.
As expected, DDSI diagnostic potential increased with increas-
ing EGFR expression level, where the highest EGFR-expressing
xenografts showed the greatest ability to differentiate between
benign and malignant tissues (Fig. 4). Interestingly, the ability
to accurately differentiation between tumor and normal tissues
was not linearly correlation with biomarker expression level.
EGFR expression level differed 10-fold between the A431 and
AsPC-1 tumors, but DDSI ROC curve calculated AUC was
nearly equivalent. MDA-MB-231 tumor EGFR expression was
about half that of the AsPC-1 tumors; however, the DDSI ROC
curve calculated AUC was much worse for the MDA-MB-231
samples when the tumor to adipose diagnostic potential was
considered (Figs. 1 and 4). Thus, a threshold in biomarker
expression level for DDSI diagnostic potential may exist,
where tumors with lower biomarker expression levels could
not be readily distinguished from normal tissue using a single
biomarker to generate DDSI. A possible solution to this diffi-
culty would be to stain for multiple biomarkers, where cancers
commonly overexpress multiple proteins that could be targeted.
The DDSI ROC curve calculated AUC values also demonstrated
that tumor-to-adipose diagnostic accuracy was substantially
more challenging to generate as compared to tumor-to-muscle
diagnostic accuracy. Tumor-to-muscle ROC curve calculated
AUCs were similar for all three tumor types even though
they differed in EGFR expression by up to ∼20-fold (Fig. 4).
This is an important point for the use of such technology to
quantitatively determine margin status for BCS, where the sur-
rounding normal tissue is largely mammary adipose. The current
study demonstrates that comparison to the accurate surrounding
normal tissue is vital for assessment of diagnostic accuracy of
ratiometric imaging methods.
The effect of biomarker spatial heterogeneity on diagnostic
accuracy of DDSI was also examined herein, where the three
model tumor types showed both homogeneous (A431) and
heterogeneous (AsPC-1 and MDA-MB-231) EGFR expression
(Figs. 2 and 3). Importantly, DDSI diagnostic potential was
found to be robust against biomarker expression heterogeneity,
where the cumulative and concentric ring analyses resulted in
similar DDSI ROC curve calculated AUC values (Figs. 4 and
5). The largest effect on DDSI diagnostic potential was seen
when concentric ring analysis was directly overlapping with
the necrotic tumor regions, which served to diminish ROC
curve calculated AUC values (Fig. 6). Fortunately, necrotic
tissue would not be expected in clinical BCS margin assess-
ment,36–38 demonstrating that robust diagnostic potential of
the DDSI method would be anticipated when comparing to
benign mammary adipose tissue.
In summary, the DDSI methodology is dependent on the tar-
geted biomarker expression level for quantitative differentiation
between benign and malignant tissues. However, DDSI shows
robust diagnostic potential even with spatial variation in bio-
marker expression. Furthermore, there appears to be a threshold
biomarker expression level required for accurate differentiation
between benign and malignant tissues using DDSI especially in
the case of comparing to normal adipose tissues. Additional
studies to define the biomarker threshold for DDSI diagnostic
potential are underway. Although these studies have focused on
BCS, this work is readily extendable to other cancer types.
Overall, the DDSI methodology provides a means for quantita-
tive margin assessment on freshly resected specimens, permit-
ting rapid clinical translation for improved patient outcomes.
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